Similarly, the expression of ARL4C in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), kidney renal papillary cell carcinoma (KIRP), pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC), and other cancer tissues increased, whereas the expression of ARL4C in BRCA (breast invasive carcinoma) and kidney chromophobe (KICH) was decreased (Figure 3(b)). Here, ARL4C is linked to invasive breast carcinoma.